These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9099222

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
    Nakagawa S, Hashizume T, Matsuda K, Sanada M, Okamoto O, Fukatsu H, Tanaka N.
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2756-9. PubMed ID: 8109950
    [Abstract] [Full Text] [Related]

  • 4. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF, Liu CP, Wang NY, Shih SC.
    BMC Infect Dis; 2016 Aug 24; 16(1):444. PubMed ID: 27553962
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY, Livermore DM.
    J Antimicrob Chemother; 1994 May 24; 33(5):949-58. PubMed ID: 8089068
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
    Sader HS, Jones RN.
    Eur J Clin Microbiol Infect Dis; 1993 May 24; 12(5):384-91. PubMed ID: 8354307
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem.
    Asahi Y, Miyazaki S, Yamaguchi K.
    Antimicrob Agents Chemother; 1995 May 24; 39(5):1030-7. PubMed ID: 7625784
    [Abstract] [Full Text] [Related]

  • 9. Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates.
    Muramatsu H, Horii T, Morita M, Hashimoto H, Kanno T, Maekawa M.
    Int J Med Microbiol; 2003 Jun 24; 293(2-3):191-7. PubMed ID: 12868655
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K, Ishida A, Chinzei T.
    Jpn J Antibiot; 2002 Apr 24; 55(2):181-6. PubMed ID: 12071095
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM, Yang YJ.
    J Antimicrob Chemother; 1989 Sep 24; 24 Suppl A():149-59. PubMed ID: 2553657
    [Abstract] [Full Text] [Related]

  • 14. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane.
    Fukuoka T, Ohya S, Narita T, Katsuta M, Iijima M, Masuda N, Yasuda H, Trias J, Nikaido H.
    Antimicrob Agents Chemother; 1993 Feb 24; 37(2):322-7. PubMed ID: 8452364
    [Abstract] [Full Text] [Related]

  • 15. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B.
    APMIS; 2005 Mar 24; 113(3):187-96. PubMed ID: 15799762
    [Abstract] [Full Text] [Related]

  • 16. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H, German Carbapenem Resistance Study Group.
    Int J Antimicrob Agents; 2020 Jun 24; 55(6):105959. PubMed ID: 32325200
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects.
    Trautmann M, Heinemann M, Zick R, Möricke A, Seidelmann M, Berger D.
    Eur J Clin Microbiol Infect Dis; 1998 Nov 24; 17(11):754-60. PubMed ID: 9923514
    [Abstract] [Full Text] [Related]

  • 18. [Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
    Arita K, Daido K, Ohashi N, Nakamura K, Takeshima Y, Kohara T.
    Jpn J Antibiot; 1999 Jul 24; 52(7):491-6. PubMed ID: 10516928
    [Abstract] [Full Text] [Related]

  • 19. [Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa].
    Hiraishi T, Miyata A, Takata T, Araake M, Ogawa H, Gotoh N, Nishino T.
    Jpn J Antibiot; 2002 Feb 24; 55(1):67-76. PubMed ID: 11977922
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H.
    Diagn Microbiol Infect Dis; 1997 Oct 24; 29(2):81-6. PubMed ID: 9368083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.